Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Serge Alexanian

Anatomic Pathology & Clinical Pathology Los Angeles, CA Medical Doctor

NPI 1437537412 CMS profile 1368879

924 Westwood Blvd, Ste. 730, Los Angeles, CA 90095

Open in the dashboard

General payments

$3,156,944

429 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Serge Alexanian of Los Angeles, CA is reported in the CMS Open Payments database as having received $3,156,944 across 429 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Anatomic Pathology & Clinical Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $775,282 90
2024 General $304,178 51
2023 General $370,285 54
2022 General $248,809 113
2021 General $538,237 38
2020 General $757,146 44
2019 General $163,008 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Serge Alexanian
  • Anatomic Pathology & Clinical Pathology median
  • Middle half of Anatomic Pathology & Clinical Pathology
  • National median

In program year 2025, general payments to Serge Alexanian were reported at $775,282. Among 2,804 Anatomic Pathology & Clinical Pathology profiles paid that year, the median was $51 and the middle half received between $24 and $149.

Show as a table
Year Serge Alexanian Anatomic Pathology & Clinical Pathology median Middle half National median
2019 $163,008 $65 $22–$150 $163
2020 $757,146 $44 $19–$144 $114
2021 $538,237 $42 $19–$142 $132
2022 $248,809 $54 $20–$140 $149
2023 $370,285 $60 $23–$157 $160
2024 $304,178 $51 $23–$145 $164
2025 $775,282 $51 $24–$149 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Agilent Technologies, Inc. $1,179,673 18 payments
  2. Incyte Corporation $889,610 83 payments
  3. Stemline Therapeutics Inc. $749,467 246 payments
  4. X4 Pharmaceuticals, Inc. $180,000 7 payments
  5. Syndax Pharmaceuticals, Inc. $102,011 41 payments
  6. Leica Microsystems Inc. $14,362 3 payments
  7. E.R. Squibb & Sons, L.L.C. $10,939 11 payments
  8. Merck Healthcare KGaA $10,625 1 payment
  9. AbbVie, Inc. $8,279 9 payments
  10. Merck KGaA $4,375 1 payment
  11. Other $7,603 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $2,887,877 189 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $226,325 55 payments
  3. Travel and Lodging $26,883 106 payments
  4. Honoraria $10,199 3 payments
  5. Food and Beverage $5,660 76 payments
Products named General payments · program years 2019–2025
  1. PD-L1 IHC 22C3 $599,168 3 payments
  2. PD-L1 IHC 22C3 pharmDx $469,915 1 payment
  3. ELZONRIS $231,175 117 payments
  4. XOLREMDI $180,000 7 payments
  5. OMNIS $71,873 5 payments
  6. PD-L1 IHC 28-8 PHARMDX $28,840 4 payments
  7. OPDIVO $9,139 10 payments
  8. ELAHERE $7,425 2 payments
  9. BOND-III processing module $7,325 1 payment
  10. VIRTUOSO System for IHC $4,000 1 payment
  11. Other $2,194 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

429 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anatomic Pathology & Clinical Pathology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record